Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 9/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.39 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.38 |
| ▸ | RNASEL | Q05823 | 3/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.36 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16373904 | 1.00 | P2RY1 (0.39) | P2RY1P2RX1P2RX3ENPP1P2RX4 | |
| SCHEMBL16368053 | 0.92 | RNASEL (0.41) | P2RY1P2RX1P2RX3ENPP1P2RX4 | |
| SCHEMBL20194538 | 0.90 | P2RY1 (0.43) | P2RY1P2RX1P2RX3ENPP1P2RX4 | |
| SCHEMBL16373936 | 0.86 | SLC29A1 (0.37) | — | |
| SCHEMBL16374032 | 0.86 | SLC29A1 (0.37) | — | |
| SCHEMBL20754594 | 0.85 | HSP90B1 (0.33) | — | |
| SCHEMBL17359765 | 0.84 | TGM2 (0.47) | P2RY6P2RY2 | |
| SCHEMBL16373901 | 0.84 | TGM2 (0.47) | P2RY6P2RY2 | |
| SCHEMBL16367965 | 0.84 | P2RX3 (0.41) | P2RY1P2RX1P2RX3ENPP1P2RX4 | |
| SCHEMBL16368315 | 0.84 | P2RX1 (0.53) | P2RY1P2RX1P2RX3P2RX4P2RY11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160318967-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2016-11-03 | — | — | US | disclosed |
| WO-2015054465-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318967-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NT5C2 | P2RY1 68/4885P2RX1 77/4885P2RX3 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.